The American Journal of Medicine
Volume 76, Issue 6 , Pages 999-1005 , June 1984

Intravenous and oral prenalterol in congestive heart failure: Effects on systemic and coronary hemodynamics and myocardial catecholamine balance

  • Dennis W. Wahr, M.D.

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California.
    • ,
  • Karl Swedberg, M.D.

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California.
    • ,
  • Michael Rabbino, M.D.

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California.
    • Current address: 1828 Camino Real, Suite 507, Burlingame, California 94010.
    • ,
  • Margaret J. Hoyle, R.N., B.S.

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California.
    • ,
  • Deirdre Curran, A.B.

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California.
    • ,
  • William W. Parmley, M.D.

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California.
    • ,
  • Kanu Chatterjee, M.B., F.R.C.P.

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Dr. Kanu Chatterjee, University of California, Moffitt 1186, San Francisco, California 94143.
    • From the Cardiovascular Division, Department of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California.

,Accepted 1 December 1983.

References 

  1. Johnsson G, Jordo L, Lundborg P, Ronn O, Fogelberg I, Wikstrand J. Haemodynamic and tolerance studies in man of a new orally active, selective β1-adrenoceptor against prenalterol (H80/60). Eur J Pharmacol. 1978;13:163–170
  2. Krans M, Pfister B, Dubach U, Imhof P. Human pharmacology studies with a new orally active stimulant of cardiac adrenergic beta receptors. Am Heart J. 1978;95:602–610
  3. Kirlin P, Pitt B. Hemodynamic effects of intravenous prenalterol in severe heart failure. Am J Cardiol. 1981;47:670–675
  4. Erbel R, Meyer J, Lambert ZH, et al. Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy. Circulation. 1982;66:361–369
  5. Ariniego R, Waagstein F, Mombay B, Hjalmarson A. Haemodynamic effects of a new β1-receptor agonist in acute myocardial infarction. Br Heart J. 1979;42:139–146
  6. Hutton B, Murray R, Boyes R, Rae A, Hollis W. Haemodynamic effects of prenalterol in patients with coronary heart disease. Br Heart J. 1980;43:134–137
  7. Waagstein F, Reiz S, Ariniego R, Hjalmarson A. Clinical results with prenalterol in patients with heart failure. Am Heart J. 1981;102:548–554
  8. Loun B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971;44:130–142
  9. Forrester JS, Ganz W, Diamond G, Meltugh T, Chonette DW, Swan HJC. Thermodilution cardiac output determination with a single flow directed catheter. Am Heart J. 1972;83:306–312
  10. Ganz W, Tamura K, Marcus HS, Donoso RR, Yoshido S, Swan HJC. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation. 1977;46:181–187
  11. Mathey DG, Chatterjee K, Tyberg JV, Lekven J, Brundage B, Parmley WW. Coronary sinus reflux: a source of error in the measurement of thermodilution coronary sinus flow. Circulation. 1978;57:778–784
  12. Dixon WJ. BMDP statistical software. Berkeley: University of California Press; 1981;
  13. Viquerat C, Swedberg K, Atherton B, et al. Increased norepinephrine (NE) and dopamine (DOP) levels and net transmyocardial release (TmR) of NE are markers of presence but not severity of chronic heart failure (abstr). Circulation. 1983;68(suppl III):III–136
  14. Sharpe N, Coxon R. Oral prenalterol in chronic heart failure (abstr). Circulation. 1982;66(suppl II):II–20
  15. Newman WH, Webb JG. A differential inotropic responsiveness to isoprenaline and ouabain in dogs with heart failure. Cardiovasc Res. 1982;14:530–537
  16. Jewitt D, Birkhead J, Mitchell A, Dollevy C. Clinical cardiovascular pharmacology of dobutamine, a selective inotropic catecholamine. Lancet. 1974;II:363–367
  17. Goldberg L. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacology. 1982;24:1–29
  18. Yamaguchi N, de Champlain J, Nadeau RA. Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic α- and β-receptors. Circ Res. 1977;41:108–117
  19. Hassle AB. Orientation on prenalterol β1-selective adrenoceptor agonist. Version II. Subsidiary of Astra Pharmaceuticals. 1980;3:3
  20. Massie B, Ports T, Chatterjee K. Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation. 1981;63:269–278

PII: 0002-9343(84)90848-9

The American Journal of Medicine
Volume 76, Issue 6 , Pages 999-1005 , June 1984

Article Tools